42533
document
Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life . BACKGROUND The prevalence of allergic rhinoconjunctivitis has increased significantly over the past decades with grass pollen being a common trigger . The impact of allergy on patient 's quality of life is substantial . AIM To investigate the sustained effect on quality of life during the grass pollen season 1 year after 3 years of treatment with the SQ-standardized grass allergy immunotherapy tablet ( AIT ) , Graza ( Phleum pratense 75,000 SQ-T/2800 BAU ; ALK , Denmark ) . METHODS The trial was a randomized , parallel-group , double-blind , placebo-controlled trial in adult subjects with a history of moderate-severe grass pollen induced rhinoconjunctivitis inadequately controlled by symptomatic medications . Subjects received 3 years of grass AIT ( n = 157 ) or placebo ( n = 126 ) , followed by 1 year of follow-up . Quality of life assessments were based on the standardized rhinoconjunctivitis quality of life questionnaire ( RQLQ ( S ) ) ; completed weekly during the entire grass pollen season . RESULTS During follow-up , the overall RQLQ ( S ) score for the entire grass pollen season was significantly improved in the active group ( relative difference to placebo : 23 % , P = 0.004 ) . The improvement was higher during the peak pollen season ( 28 % , P = 0.001 ) . The treatment effect of grass AIT during the follow-up year and the previous three treatment years was similar . Improvements were found in all seven RQLQ ( S ) domains . The RQLQ ( S ) as a function of the weekly average pollen counts showed a clear separation between the treatment groups ( P < 0.001 ) . CONCLUSION In subjects inadequately controlled by symptomatic medications , grass AIT provided sustained and clinically relevant improvements in rhinoconjunctivitis quality of life compared to placebo . The effect increased with increasing grass pollen exposure .
42534
Intervention_Pharmacological
immunotherapy tablet
42535
Intervention_Pharmacological
grass allergy immunotherapy tablet ( AIT )
42536
Intervention_Pharmacological
grass AIT
42537
Intervention_Control
placebo
42538
Intervention_Pharmacological
AIT
42539
Outcome_Other
Quality of life
42540
Outcome_Other
standardized rhinoconjunctivitis quality of life questionnaire ( RQLQ ( S ) )
42541
Outcome_Other
RQLQ ( S ) score
42542
Outcome_Other
RQLQ ( S ) domains
42543
Outcome_Other
RQLQ ( S )
42544
Outcome_Physical
rhinoconjunctivitis quality of life
42545
Participant_Age
adult
42546
Participant_Condition
moderate-severe grass pollen induced rhinoconjunctivitis inadequately controlled by symptomatic medications